![](https://cdn.sanity.io/images/0vv8moc6/onclive/ba6ffd370593b41bb1ab9d8bdecea6c242f6f114-200x200.png?fit=crop&auto=format)
ODAC Votes to Require Within Trial Assessment of Neoadjuvant vs Adjuvant Treatment Benefit in Perioperative Trial ...
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 11 to 0 that the regulatory body should require adequate within trial assessment of contribution of treatment phase in new trial design proposals for perioperative regimens for resectable non–small …